Goldline Pharmaceutical FY26 net profit rises 45% to ₹411.71 lakh
Goldline Pharmaceutical Limited reported a 45.2% rise in net profit to ₹411.71 lakh for FY26, with revenue increasing 11.2% to ₹3,119.76 lakh. The Board approved the audited results on June 09, 2026, and appointed M/s. Kunal Dutt & Associates as Internal Auditor.
*this image is generated using AI for illustrative purposes only.
Goldline Pharmaceutical Limited reported a 45.2% rise in net profit to ₹411.71 lakh for the financial year ended March 31, 2026, compared to ₹283.43 lakh in the previous year. The company's revenue from operations increased 11.2% to ₹3,119.76 lakh from ₹2,805.57 lakh in FY25, driven by growth in its wholesale trade of pharmaceuticals business. Total income for the year stood at ₹3,119.88 lakh, up from ₹2,805.57 lakh in the prior year.
The Board of Directors approved the standalone audited financial results for the half-year and year ended March 31, 2026, at a meeting held on June 09, 2026. The results were reviewed by the Audit Committee and received an unmodified opinion from the statutory auditor, B Shroff & Co. The company was listed on the BSE SME Platform on May 19, 2026, subsequent to the reporting period.
Financial Performance
Profit before tax for FY26 increased to ₹538.54 lakh from ₹385.84 lakh in the previous year. Total expenses for the year rose to ₹2,581.34 lakh from ₹2,419.73 lakh, primarily due to higher employee benefit costs and purchases. Earnings per share (basic and diluted) improved to ₹5.97 from ₹4.11 in the prior year.
| Particulars | Year Ended March 31, 2026 (₹ in Lacs) | Year Ended March 31, 2025 (₹ in Lacs) |
|---|---|---|
| Revenue from operations | 3,119.76 | 2,805.57 |
| Total Income | 3,119.88 | 2,805.57 |
| Total Expenses | 2,581.34 | 2,419.73 |
| Profit Before Tax | 538.54 | 385.84 |
| Net Profit | 411.71 | 283.43 |
| Earnings Per Share (Basic) | 5.97 | 4.11 |
Balance Sheet and Cash Flows
The company's shareholder funds improved to ₹1,424.96 lakh as of March 31, 2026, compared to ₹1,026.03 lakh in the previous year, driven by an increase in reserves and surplus. Total assets stood at ₹2,887.09 lakh, up from ₹2,618.70 lakh. Cash and cash equivalents decreased to ₹59.24 lakh from ₹123.97 lakh at the end of the previous year.
Cash flow from operating activities for the year was ₹281.46 lakh, down from ₹318.12 lakh in FY25. The company utilized ₹340.41 lakh in financing activities, mainly towards repayment of borrowings and finance costs. Net cash and cash equivalents decreased by ₹64.73 lakh during the year.
Board Appointments
The Board appointed M/s. Kunal Dutt & Associates, Practicing Company Secretaries, as the Internal Auditor of the company for the financial year 2026-27 onwards. The firm is not related to any director or key managerial personnel of the company.
Historical Stock Returns for Goldline Pharmaceutical
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.97% | -10.91% | -24.59% | -24.59% | -24.59% | -24.59% |
How will the recent listing on the BSE SME Platform impact Goldline Pharmaceutical's ability to raise capital for future expansion?
What strategies will the company employ to manage the significant decrease in cash and cash equivalents moving forward?
Will the company continue to prioritize debt repayment, or will it shift focus to investing in growth opportunities given the improved profitability?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
